Cesana Beatrice, Cochet Claude, Filhol Odile
University Grenoble Alpes, INSERM, CEA, IRIG-Biosanté, UMR 1292, Grenoble, France.
Int J Cancer. 2025 Feb 1;156(3):475-487. doi: 10.1002/ijc.35181. Epub 2024 Sep 22.
Approximately one-third of advanced renal cell carcinoma (RCC) patients develop osteolytic bone metastases, leading to skeletal complications. In this review, we first provide a comprehensive perspective of seminal studies on bone metastasis of RCC describing the main molecular modulators and growth factor signaling pathways most important for the RCC-stimulated osteoclast-mediated bone destruction. We next focus on newer developments revealing with in-depth details, the bidirectional interplay between renal cancer cells and the immune and stromal microenvironment that can through epigenetic reprogramming, profoundly affect the behaviors of transformed cells. Understanding their mechanistic interactions is of paramount importance for advancing both fundamental and translational research. These new investigations into the landscape of RCC-bone metastasis offer novel insights and identify potential avenues for future therapeutic interventions.
大约三分之一的晚期肾细胞癌(RCC)患者会发生溶骨性骨转移,导致骨骼并发症。在本综述中,我们首先全面介绍了关于RCC骨转移的开创性研究,描述了对RCC刺激破骨细胞介导的骨破坏最重要的主要分子调节因子和生长因子信号通路。接下来,我们重点关注最新进展,深入详细地揭示肾癌细胞与免疫和基质微环境之间的双向相互作用,这种相互作用可通过表观遗传重编程深刻影响转化细胞的行为。了解它们的机制相互作用对于推进基础研究和转化研究至关重要。这些对RCC骨转移情况的新研究提供了新的见解,并确定了未来治疗干预的潜在途径。